We are a global specialty pharmaceutical company with headquarter in Switzerland and committed to development and commercialization of innovative medicines to meet the needs of patients living with rare diseases.
Our portfolio comprises clinical stage and marketed treatments for neuro-ophthalmological, neuromuscular and pulmonary diseases that currently lack treatment options, such as Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD), Congenital Muscular Dystrophy (CMD) and Cystic Fibrosis (CF).
We have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases. We are passionate about improving patients’ quality of life and our vision is to be a leader in providing treatments for rare diseases in these areas with high unmet medical needs.
For more information about Santhera, please visit the company's website www.santhera.com